Market Research Logo

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Vaginal Atrophy (Atrophic Vaginitis) Overview
Therapeutics Development
Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies
Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development
Allergan Plc
EndoCeutics, Inc.
Foamix Pharmaceuticals Ltd.
Ligand Pharmaceuticals, Inc.
Pantarhei Bioscience BV
Peptonic medical AB
RestorGenex Corporation
TherapeuticsMD Inc.
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
esterol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
estradiol hemihydrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lasofoxifene tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
prasterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RES-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TX-004HR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WC-3011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaginal Atrophy (Atrophic Vaginitis) - Recent Pipeline Updates
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects
Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones
Featured News & Press Releases
Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting
Sep 09, 2015: TherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting
Aug 05, 2015: TherapeuticsMD Receives Patent Allowance for VVA Candidate TX-004HR
Jul 17, 2015: Last subject exits Peptonic Medical’s phase 2b VVA study
Mar 30, 2015: Vulvovaginal atrophy symptoms improve with prasterone treatment
Mar 23, 2015: Peptonic Medical’s formulation patent to be approved in the USA
Mar 18, 2015: Patient recruitment to Peptonic Medical’s phase 2b study soon completed
Mar 09, 2015: Physicians Visual Assessments Correlate with Objective Measurements of Postmenopausal VVA Patients Treated with TX-004HR VagiCap
Feb 20, 2015: Survey Shows Postmenopausal Women with VVA Reported Improved Satisfaction and Quality of Life with VagiCap Investigational Local Estrogen Treatment
Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Allergan Plc, H2 2015
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H2 2015
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Pantarhei Bioscience BV, H2 2015
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Peptonic medical AB, H2 2015
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by RestorGenex Corporation, H2 2015
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Recent Pipeline Updates, H2 2015
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2015
Number of Products under Development by Companies, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2015’, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Vaginal Atrophy (Atrophic Vaginitis) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Vaginal Atrophy (Atrophic Vaginitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Vaginal Atrophy (Atrophic Vaginitis) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;